Drugs / Bakuchiol
Bakuchiol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03112863 | Mar 2017 → Mar 2019 | — | University of California, Davis | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07477288 | Mar → Sep 2025 | skin atrophy | Hasanuddin University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06833996 | Feb 2016 → May 2018 | hyperpigmentation of the skin | Henry Ford Health System | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bakuchiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07477288 ↗ |
| Known as | (s)-bakuchiol | ChEMBL registry synonym — accepted as the source's own label CHEMBL262344 ↗ |
| Known as | Sytenol a | ChEMBL registry synonym — accepted as the source's own label CHEMBL262344 ↗ |
| Known as | UP 256 | ChEMBL registry synonym — accepted as the source's own label CHEMBL262344 ↗ |
| Action | Inhibit | “bakuchiol had inhibitory effects on melanin synthesis” NCT06833996 ↗ |
| Modality | Small molecule | “Bakuchiol is a meroterpene phenol derived from plant sources” NCT06833996 ↗ |
| Route | Topical | “Bakuchiol 0.5% applied to face twice daily” NCT03112863 ↗ |